9 results about "Leptospira" patented technology

The application provides a primer probe set, a kit and application for quantitatively detecting murine infectious agents, and belongs to the technical field of genetic engineering.The six-reagent quantitative detection kit (fluorescent PCR method) for tsutsugamushi oriental body, fever with thrombocytopenia syndrome virus, prrillonella, hantavirus, leptospira, and rickettsia mooseri can detect the six pathogenic targets of tsutsugamushi oriental body, fever with thrombocytopenia syndrome virus, prrillonella, hantavirus, leptospira, and rickettsia mooseri in one reaction, and accurately quantitatively analyzes each pathogenic target.Through single-tube reaction, parallel detection and quantification of the six pathogenic targets are realized, the time consumed due to misjudgment of the targets is reduced, the consumption of consumables and the occupation of instrument space caused by multi-tube reaction are reduced.The quantitative results reflect the pathogenic load, and provide efficient detection and application support for rapid identification and quantitative monitoring of samples of murine origin or samples of the environment related to mouse activities.

The invention provides a vaccine prepared from Gleisseria parasuis SmpA protein and related tandem protein thereof and application, and belongs to the technical field of veterinary biological products. The invention relates to a vaccine prepared from a Gleisseria parasuis SmpA protein, and further relates to recombinant proteins SmpA-OppA1 and OppA1-SmpA which are expressed in a tandem manner, and recombinant proteins SmpA-PalA and PalA-SmpA which are expressed in a tandem manner, namely SmpA and OppA1 recombinant proteins SmpA-OppA1 and OppA1-SmpA. Experiment results show that the SmpA protein, the SmpA-OppA1 and OppA1-SmpA, and the SmpA-PalA and PalA-SmpA all have the obvious advantage and characteristic of strong immune protection efficacy, and after the SmpA protein, the SmpA-OppA1 and OppA1-SmpA as well as the SmpA-PalA and PalA-SmpA are mixed with an adjuvant, the prepared swine Graisseria subunit vaccine has the advantages of simple process and good safety, can effectively resist the infection of Graisseria parasuis, and lays a foundation for industrial production of the swine Graisseria subunit vaccine.

The present invention relates to a combination of a first vaccine comprising a non-replicating immunogen of porcine erysipelothrix sp. And a non-replicating immunogen of porcine parvovirus and a second vaccine comprising a non-replicating immunogen of leptospira sp. And the first vaccine and the second vaccine are jointly injected into corium layers of a first injection part and a second injection part of the pig at different points to prophylactically treat the pig so as to resist swine erysipelothrix erysipelas infection, porcine parvovirus infection and leptospirosis infection.

The invention provides a mutant of phenylalanine tRNA (transfer ribonucleic acid) alpha subunit synthetase mPheS of rhinotrichum gloeosporioides, which has T257A and A304G double-site mutation relative to a wild type amino acid sequence, the invention further provides a coding gene of the mutant, and the gene of the mutant is applied to microbial gene knockout. An efficient gene traceless knockout strategy of the rhinotrichum-like is established, and efficient gene traceless knockout of the rhinotrichum-like can be achieved.

The invention provides a virulence modifying (VM) protein-based composition or vaccine for administration to a subject, comprising a recombinant VM protein antigen or a recombinant viral vector expressing a VM protein antigen and a pharmaceutically or veterinarily acceptable adjuvant. The invention further provides a method for vaccinating a subject susceptible to leptospirosis infection or eliciting an immune response in the subject against leptospirosis comprising administering the vaccine to the subject. The invention also provides a method for diagnosing leptospirosis in a subject by quantifying the presence of a secreted, leptospiral VM protein antigen that mediates disease pathogenesis in the subject.

The invention provides a virulence modifying (VM) protein-based composition or vaccine for administration to a subject, comprising a recombinant VM protein antigen or a recombinant viral vector expressing a VM protein antigen and a pharmaceutically or veterinarily acceptable adjuvant. The invention further provides a method for vaccinating a subject susceptible to leptospirosis infection or eliciting an immune response in the subject against leptospirosis comprising administering the vaccine to the subject. The invention also provides a method for diagnosing leptospirosis in a subject by quantifying the presence of a secreted, leptospiral VM protein antigen that mediates disease pathogenesis in the subject.

The application relates to the technical field of molecular biology detection, and specifically discloses a Leptospira rapid detection kit based on CRISPR-Cas12a, which comprises an amplification module reagent, a CRISPR detection module reagent, a sample pretreatment module reagent and a quality control module reagent; the double-target strategy can realize the following advantages through complementary identification information: on one hand, a pathogenic gene directly indicates a potential pathogenic strain, and the direct indication can enhance the directionality of disease correlation; on the other hand, a 16S variable region provides lineage or close strain identification, and can distinguish environmental / non-pathogenic background noise from a real pathogenic threat. The design reduces the risk of false positive or false negative caused by a single target in molecular recognition, improves the reliability and availability of detection results in clinical interpretation and epidemiological explanation, and provides more definite information support for subsequent diagnosis and treatment or prevention and control decision-making after rapid screening.

The invention provides compositions and methods for using Leptospiral virulence modifying (VM) proteins or fragments or fusions thereof, as vaccines and as therapeutic agents for the treatment of cancer.

The application discloses a canine leptospira, icterohaemorrhagia leptospira and canine coronavirus triple inactivated vaccine. The application is prepared by adding adjuvant after inactivation of the canine leptospira, icterohaemorrhagia leptospira and canine coronavirus epidemic strain separated in China. The application relates to a pathogen separation culture, identification, inactivation method, production process, vaccine storage and immunization method. The canine triple inactivated vaccine is used for preventing canine leptospira disease, icterohaemorrhagia leptospira disease and canine coronavirus disease, and high antibodies can be generated after immunization of the canine, and the high antibodies have a good protective effect on virulent attack. The leptospira is a zoonosis, the canine is a companion animal of human, and the pet canine is in close contact with human, so the triple inactivated vaccine has good social benefits and important public health significance.